Skip to main content
. Author manuscript; available in PMC: 2010 Jan 19.
Published in final edited form as: Hepatology. 2007 Nov;46(5):1548–1563. doi: 10.1002/hep.21853

Fig. 1.

Fig. 1

Study design. The patients in the on-treatment group were given either 180 μg of peginterferon-alpha 2a subcutaneously 24 hours prior to liver biopsy or 1000/1200 mg of ribavirin daily for 72 hours plus 180 μg of peginterferon-alpha 2a subcutaneously 24 hours prior to liver biopsy. After the biopsy, the patients were continued on the therapy for 48 weeks.